image: IL-2 immunotherapy expands tumor-infiltrating DCs through a lymphoid pathway, favoring the conversion of poorly immunogenic into immunogenic tumors. This material relates to a paper that appeared in the Sep. 16, 2020, issue of Science Translational Medicine, published by AAAS. The paper, by M.E. Raeber at University Hospital Zurich in Zurich, Switzerland; and colleagues was titled, "Interleukin-2 signals converge in a lymphoid-dendritic cell pathway that promotes anticancer immunity." view more
Credit: [Credit: <i>Raeber et al</i>.]